Byetta outperforms Januvia in diabetes study

09/10/2008 | Bloomberg

A study of 61 patients showed that Byetta, a diabetes drug from Amylin Pharmaceuticals and Eli Lilly and Co., decreased blood-sugar levels and reduced appetite better than Januvia, a rival medicine from Merck & Co. The findings demonstrate "a clear difference in the method of actions" between the two products amid confusion in the marketplace about their therapeutic qualities, one of the researchers said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI